MX388527B - Composiciones adyuvantes y metodos relacionados. - Google Patents

Composiciones adyuvantes y metodos relacionados.

Info

Publication number
MX388527B
MX388527B MX2017006744A MX2017006744A MX388527B MX 388527 B MX388527 B MX 388527B MX 2017006744 A MX2017006744 A MX 2017006744A MX 2017006744 A MX2017006744 A MX 2017006744A MX 388527 B MX388527 B MX 388527B
Authority
MX
Mexico
Prior art keywords
present disclosure
related methods
composition
adjuvant compositions
adjuvant composition
Prior art date
Application number
MX2017006744A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006744A (es
Inventor
Mary Ann Pfannenstiel
Timothy J Miller
Original Assignee
Huvepharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huvepharma Inc filed Critical Huvepharma Inc
Publication of MX2017006744A publication Critical patent/MX2017006744A/es
Publication of MX388527B publication Critical patent/MX388527B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2017006744A 2014-11-26 2015-11-27 Composiciones adyuvantes y metodos relacionados. MX388527B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084698P 2014-11-26 2014-11-26
US201562137659P 2015-03-24 2015-03-24
PCT/US2015/062836 WO2016086222A1 (en) 2014-11-26 2015-11-27 Adjuvant compositions and related methods

Publications (2)

Publication Number Publication Date
MX2017006744A MX2017006744A (es) 2017-08-16
MX388527B true MX388527B (es) 2025-03-20

Family

ID=56075072

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006744A MX388527B (es) 2014-11-26 2015-11-27 Composiciones adyuvantes y metodos relacionados.

Country Status (9)

Country Link
EP (1) EP3223846B1 (enExample)
JP (1) JP6802790B2 (enExample)
AU (1) AU2015353376B2 (enExample)
CA (1) CA2968389C (enExample)
DK (1) DK3223846T3 (enExample)
ES (1) ES2961965T3 (enExample)
MX (1) MX388527B (enExample)
PL (1) PL3223846T3 (enExample)
WO (1) WO2016086222A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
EP3273950A4 (en) * 2015-03-24 2019-04-24 Vaxliant, LLC ADJUVANE COMPOSITIONS AND RELATED METHODS
US11813321B2 (en) 2018-07-13 2023-11-14 Biomune Company Vaccines against avian reoviruses
CA3147040A1 (en) 2019-07-12 2021-01-21 Biomune Company Method for vaccinating avians against reovirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
NZ727616A (en) * 2008-06-27 2018-06-29 Zoetis Services Llc Novel adjuvant compositions
AU2013204906B2 (en) * 2012-03-12 2016-01-07 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
EP3786298A1 (en) * 2012-11-01 2021-03-03 Factor Bioscience Inc. Methods and products for expressing proteins in cells

Also Published As

Publication number Publication date
JP2017537106A (ja) 2017-12-14
AU2015353376A1 (en) 2017-06-08
EP3223846B1 (en) 2023-09-06
DK3223846T3 (da) 2023-11-20
CA2968389C (en) 2023-12-12
EP3223846A4 (en) 2018-07-25
EP3223846A1 (en) 2017-10-04
MX2017006744A (es) 2017-08-16
PL3223846T3 (pl) 2024-03-11
BR112017010883A2 (pt) 2017-12-26
AU2015353376B2 (en) 2021-03-25
CA2968389A1 (en) 2016-06-02
ES2961965T3 (es) 2024-03-14
NZ731929A (en) 2024-09-27
WO2016086222A1 (en) 2016-06-02
JP6802790B2 (ja) 2020-12-23

Similar Documents

Publication Publication Date Title
MX390860B (es) Composiciones adyuvantes y metodos relacionados.
EA201790398A1 (ru) Способы лечения заболевания печени
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
TW201613556A (en) Swine virus vaccines that are liquid stable
EP3012322A4 (en) GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
BR112018012873A2 (pt) vacina de vírus zika
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX385109B (es) Formulaciones de anticuerpos.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX381211B (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
MX390304B (es) Proceso para preparar una vacuna tetravalente atenuada contra el dengue.
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
EA201891342A1 (ru) Изоиндольные соединения
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX388527B (es) Composiciones adyuvantes y metodos relacionados.
MX2016012932A (es) Procedimientos novedosos para inducir una respuesta inmune.